Access to anti-retroviral drugs, female in Guyana

Guyana: Access to anti-retroviral drugs, female was 75.0% in 2024. ◆ Volatile

Latest (2024)
75.0%
Change on year
up 2.7%
World rank
67th
of 141 countries
All-time high
75.0%
in 2019
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Guyana, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 3 %2004: 11 %2005: 25 %2006: 33 %2007: 39 %2008: 46 %2009: 52 %2010: 54 %2011: 59 %2012: 62 %2013: 66 %2014: 67 %2015: 69 %2016: 71 %2017: 72 %2018: 71 %2019: 75 %2020: 72 %2021: 71 %2022: 72 %2023: 73 %2024: 75 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Guyana stood at 75.0%. That is the highest value across all 25 years on record.

That represents a change of up 2.7% on the previous year and up 11.9% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Guyana peaked at 75.0% in 2019 and was at its lowest, 0.0%, in 2000.

Guyana ranks 67th of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Guyana, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Guyana, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 3.0%
2004 11.0% +266.7%
2005 25.0% +127.3%
2006 33.0% +32.0%
2007 39.0% +18.2%
2008 46.0% +17.9%
2009 52.0% +13.0%
2010 54.0% +3.8%
2011 59.0% +9.3%
2012 62.0% +5.1%
2013 66.0% +6.5%
2014 67.0% +1.5%
2015 69.0% +3.0%
2016 71.0% +2.9%
2017 72.0% +1.4%
2018 71.0% -1.4%
2019 75.0% +5.6%
2020 72.0% -4.0%
2021 71.0% -1.4%
2022 72.0% +1.4%
2023 73.0% +1.4%
2024 75.0% +2.7%

Averages by decade

DecadeAverage LowestHighest Years
2000s 20.9% 0.0% 52.0% 10
2010s 66.6% 54.0% 75.0% 10
2020s 72.6% 71.0% 75.0% 5

Countries ranked near Guyana

  1. 64 Bahamas 76.0% compare
  2. 64 Honduras 76.0% compare
  3. 64 Oman 76.0% compare
  4. 67 Ecuador 75.0% compare
  5. 69 Comoros 74.0% compare
  6. 69 El Salvador 74.0% compare

See the full ranking of 160 places →

More gender data for Guyana

All data for Guyana →

Frequently asked questions

What is access to anti-retroviral drugs, female in Guyana?
Access to anti-retroviral drugs, female in Guyana was 75.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Guyana?
The highest recorded value was 75.0% in 2019.
What is the lowest access to anti-retroviral drugs, female recorded in Guyana?
The lowest recorded value was 0.0% in 2000.
How does Guyana rank for access to anti-retroviral drugs, female?
Guyana ranks 67th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Guyana?
Over the last ten years it is up 11.9%. The long-run trend across the full record is volatile.
Where does this Guyana data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Guyana. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/guyana/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/guyana/">Access to anti-retroviral drugs, female in Guyana</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.